Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0153690 (
bone metastases
)
6,382
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Bone metastases
occur in most advanced breast cancer patients and cause serious skeletal-related complications. The mechanisms by which bone metastasis seeds develop in primary tumors and specifically colonize the bone remain to be elucidated. Here, we show that
forkhead box F2
(
FOXF2
) functions as a master transcription factor for reprogramming cancer cells into an osteomimetic phenotype by pleiotropic transactivation of the BMP4/SMAD1 signaling pathway and bone-related genes that are expressed at early stages of bone differentiation. The epithelial-to-osteomimicry transition regulated by
FOXF2
confers a tendency on cancer cells to metastasize to bone which leads to osteolytic bone lesions. The BMP antagonist Noggin significantly inhibits
FOXF2
-driven osteolytic bone metastasis of breast cancer cells. Thus, targeting the
FOXF2
-BMP/SMAD axis might be a promising therapeutic strategy to manage bone metastasis. The role of
FOXF2
in transactivating bone-related genes implies a biological function of
FOXF2
in regulating bone development and remodeling.
...
PMID:FOXF2 reprograms breast cancer cells into bone metastasis seeds. 3122 4